[PRC HOME]
  Preceptorship | Residency | Fellowship | Certificate | Research  
University at Buffalo, the State University of New York School of Pharmacy and Pharmaceutical Sciences
 

HIV Articles & Updates

HIV Articles
Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations (NRTI mutations)
Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations: TDM

IL-2 Therapy Effective in Acute HIV & HAART

Long-term safety of discontinuation of secondary prophylaxis against Pneumocystis pneumonia: Prospective multicentre study

CCR5 Inhibitor Prevents HIV transmission in Monkeys

Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure

Can HIV Be Eradicated?

FDA Grants Full traditional Approval for Fuzeon

Steady-State Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir/Fosamprenavir in HIV-1-Infected Patients

Vitamin D & HIV

Early Research on Integrase Inhibitors: 2 classes of compounds identified

Roche and Trimeris Open Physician Enrollment For Fuzeon(TM) U.S. Early Access Program

Recent HIV Information
Forum for Collaborative HIV Research
Antiretroviral Updates
 

 


© 2005 ePharmacotherapy Networks. All rights reserved.
371 Cooke Hall - Buffalo, NY 14260-1200
Last Modified: Monday, 19-Jun-2006 09:38:16 EDT
Usage Statistics